All News

Article

ICYMI: Spondyloarthritis Innovations

Robert Chao, MD May 22, 2023

The second day of RheumNow Live 2023 held in March ended with a focus on axial spondyloarthritis, especially on the evaluation of the definition of the disease, the inheritance of it, and of course the treatment of it.

Article

Allergic Drug-Induced Arthritis (5.19.2023)

Jack Cush, MD May 19, 2023

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.

Article

Juvenile and Adult-onset Scleroderma Differ

Jack Cush, MD May 15, 2023

A retrospecitve cohort comparision of juvenile (jSSc) and adult-onset (aSSc) systemic sclerosis (SSc) are both rare but present differently.

Article

ICYMI: Our old friend, hydroxychloroquine

Eric Dein, MD May 15, 2023

After an action packed weekend, RheumNow Live 2023 concluded on Sunday with a half-day session on systemic lupus erythematous and ankylosing spondylitis discussing many new medications that are revolutionizing rheumatology. Dr. Laurent Arnaud, a professor at Strasbourg University in France, however, took the time to review one of our oldest therapies: hydroxychloroquine.

Article

One in Ten is Bad! (5.12.2023)

Jack Cush, MD May 12, 2023

This week on the Podcast Dr. Jack Cush reviews the news and journal articles, including the risks of dying, developing RA or autoimmune disease!

Dr. Anisha Dua on Imaging in PMR: - US of shoulders to eval for bursitis can increase specificity - MRI better for pelvic girdle, but expensive - Consider PET if lack of response to steroids, r/o malignancy #RNL2023 @RheumNow https://t.co/tjhGlJPDWZ https://t.co/9h1FwfM0CP

https://bit.ly/3WflJpm

Dr. Langford's take home for GPA. Remember to consider disease severity (will determine tx,) maintenance tx, and non-medical management including vaccination options for pts. #RNL2023 @RheumNow https://t.co/R6nrz7YXZr https://t.co/UVY0jDUGJ2

https://bit.ly/3BDoJTa

Avacopan in GPA - non-inferior to prednisone for induction remission - received FDA approval for treatment of severe active GPA in combo with standard therapy and steroids - should be used in newly diagnosed active or relapsing disease @rheumnow #RNL2023 https://t.co/My6M5MGBl1 https://t.co/0aPFUeE55Q

https://bit.ly/3BAxm0L

Dr. Langford #RNL2023 When to use CYC over RTX for severe GPA induction? - Severe disease with RTX intolerance - Worsening disease despite RTX - RGPN Cr > 4.0, mechanical ventilation? (these were excluded from RAVE trial) @RheumNow https://t.co/AnSAnGP6Oa https://t.co/iHF6tiFvj2

https://bit.ly/3od8sRH

"Highest pre-test probability for GCA is actually: 1) Limb claudication 2) Jaw claudication #RNL2023 @RheumNow https://t.co/Ed52fIcVaI" https://t.co/dA1FlCEU3i

https://bit.ly/434RYKb

GCA biopsy: When and How Early is best, rec'd in first 2 weeks. Findings can be present at 8 weeks but be less prominent @anisha_dua rec's unilateral imaging in most pts, especially w scalp tenderness on one side >1 cm length #RNL2023 @RheumNow https://t.co/Pn25Qt0WL4 https://t.co/5qROaTbD2w

https://bit.ly/3OrFx7j

Dr. Spiera's approach to PMR treatment - prefers methylprednisolone - rapid taper over 16 weeks - consider GC sparing therapy (MTX, IL-6i) @Rheumnow #RNL2023 https://t.co/LR9e0aXkeN https://t.co/qXUBkz5vfe

https://bit.ly/45ewJYk

Conaghan shares unpublished data from PROMOTE study at #RNL2023 Early data shows MTX benefits pain in patients w/ OA, particularly more metabolically active. Looking forward to more data on this-- https://t.co/Zfh7CbqvPi https://t.co/kIYKRFtUX2

https://bit.ly/3IbZjQ4

DMARDs/TNF for PMR: MTX- initial benefit, but no 5 year steroid sparing effect Infliximab - no benefit Lef - some benefit in case series Robert Spiera #RNL2023 @RheumNow https://t.co/d7BpmxFfct https://t.co/jLJDPuMtD3

https://bit.ly/3M6DLWh

#RNL2023 Rob Spiera: I often use aspirin a day, especially if cranial complications and no contra-indications" No prospective studies, 2 large retrospective studies suggesting benefit @RheumNow https://t.co/V8C43LN5wl https://t.co/2focIzWhPP

https://bit.ly/3BAhVFy

One in Ten is Bad! This week on the Podcast Dr. Jack Cush reviews the news and journal articles, including the risks of dying, developing RA or autoimmune disease! https://t.co/5SXPotfhs0 https://t.co/jXwsWoltsy

https://bit.ly/3pIGspy

Watch: Meetings should be like Oktoberfest https://t.co/pZGOYXINir https://t.co/RIXmpRztaL

https://bit.ly/3I7pR55

Tuesday Night Rheumatology: POD 3: Vasculitis: Evolution and Advances This webinar will feature highlights from these lectures followed by live audience Q & A: -New Therapies for PMR & GCA -Assessment of GCA and PMR -GPA Treatment Choices https://t.co/PRj6QQnxIS https://t.co/Y4aCyTrg0Z

https://bit.ly/3LZcq8n

Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/0mC7PxF0DU https://t.co/klbnwjcPbM